Semax vs Selank: which neuropeptide is right for your research?

If you spend time in the research peptide community, two names come up together more than any others: Semax and Selank. Both were developed at the Institute of Molecular Genetics in Moscow. Both are delivered intranasally. Both target the central nervous system. But they do very different things through very different mechanisms — and understanding those differences is critical to designing the right research protocol.

Semax is a cognitive performance peptide. It upregulates brain-derived neurotrophic factor (BDNF), sharpens focus, and has been studied for neuroprotective applications including stroke recovery. It makes you sharper.

Selank is an anxiolytic nootropic. It modulates GABA and serotonin systems to produce calm alertness without the sedation or dependence profile of benzodiazepines. It makes you calmer — without making you dull.

The Semax vs Selankquestion is not about which one is “better” — it is about which mechanism your research protocol requires. And increasingly, the answer is both.

Origin and structure

Semax is a synthetic heptapeptide based on the ACTH(4-10) fragment — the biologically active portion of adrenocorticotropic hormone involved in attention, memory, and learning. The molecule was engineered with a Pro-Gly-Pro tail that dramatically extends its half-life, making it viable for intranasal delivery where most peptides this short would degrade before reaching target receptors.

Mechanism of action

The primary mechanistic finding for Semax is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the hippocampus and cortex. BDNF is the master growth factor for synaptic plasticity — the molecular substrate of learning and memory formation. Semax has been shown to increase BDNF expression by up to 4-fold in rodent models, which is a larger effect than most pharmaceutical compounds targeting the same pathway.

Secondary mechanisms include modulation of serotonin and dopamine metabolism, with researchers reporting increased turnover of both neurotransmitters in cortical regions. This dual-monoamine effect may explain the cognitive-motivational effects reported across multiple preclinical studies.

Research applications

• Memory formation and retrieval protocols
• Neuroprotection and stroke recovery models
• Attention and cognitive performance under stress
• BDNF-dependent neuroplasticity studies
• Cognitive decline prevention in aging models

Semax has been approved in Russia as a prescription nootropic since 2011, giving it one of the longer real-world track records of any research neuropeptide. View Semax nasal spray in our catalog.

Origin and structure

Selank is a synthetic analogue of tuftsin — an immunomodulatory tetrapeptide naturally produced by the spleen. The Selank molecule extends tuftsin with a Gly-Pro extension that stabilizes it against enzymatic degradation and enables effective intranasal delivery. Like Semax, it was developed at the Russian Academy of Sciences and has been approved in Russia for clinical use as an anxiolytic.

Mechanism of action

Selank’s anxiolytic profile stems from its interaction with the GABAergic system. It enhances the expression of GABA-A receptor subunits in limbic structures, producing anxiolytic effects comparable to benzodiazepines in rodent models — but without the sedation, cognitive impairment, or dependence liability that make benzodiazepines problematic for sustained use.

Additionally, Selank modulates serotonin metabolism, specifically influencing the balance of serotonin and its metabolites in the hippocampus. This dual GABA-serotonin modulation creates a profile that researchers describe as “calm focus” — reduced anxiety with preserved or enhanced cognitive function.

Selank also has documented immunomodulatory effects inherited from its tuftsin parent structure, including modulation of cytokine expression (IL-6 and IL-10 in particular). This makes it relevant to researchers studying neuroinflammation-anxiety connections.

Research applications

• Anxiety models without sedation confounds
• GABA system modulation studies
• Stress resilience and HPA-axis regulation
• Neuroinflammation and neuroimmunology
• Mood stabilization protocols

View Selank nasal spray in our catalog.

The core takeaway: Semax vs Selank is not an either-or competition. They target different sides of cognitive performance. Semax drives the accelerator (BDNF, dopamine, focus). Selank releases the brake (GABA, serotonin, anxiety reduction). The most interesting research protocols use both.

The Semax-Selank stack is the single most popular neuropeptide combination in the research community, and for good reason. The peptides target complementary pathways — cognitive drive and emotional regulation — without pharmacological overlap.

Common stacking protocols in the research community follow a simple pattern: Semax in the morning for cognitive demand periods, Selank when anxiety or stress variables need to be controlled. Some protocols alternate them; others run them in tandem with temporal separation.

We offer a pre-paired Selank + Semax Stack that ships both sprays together at a discount — the most popular item in our catalog after BPC-157.

The decision tree is straightforward:

• Your protocol prioritizes cognitive enhancement, memory, or neuroprotection → Start with Semax.
• Your protocol prioritizes anxiolysis, stress resilience, or neuroimmunology → Start with Selank.
• Your protocol needs both cognitive sharpness and emotional regulation → Get the Selank + Semax Stack.

In practice, most researchers who try one end up adding the other within a few weeks. The mechanisms are genuinely complementary, and the intranasal format makes running both logistically simple.

Both Semax and Selank are sensitive to degradation in solution. When sourcing either peptide in nasal spray format, the same quality criteria apply: HPLC-verified purity at 99%+, batch-matched COA with mass spec confirmation, cold-chain shipping, and pharmaceutical-grade atomizer hardware.

Avoid suppliers who cannot provide documentation specific to the batch you are purchasing. A generic COA tells you what the supplier synthesized at some point — not what is in the vial they are shipping to you today.

For a detailed walkthrough on evaluating supplier documentation, read our guide to reading peptide COAs.